|
gptkbp:instanceOf
|
anticonvulsant
hydantoin derivative
|
|
gptkbp:ATCCode
|
N03AB03
|
|
gptkbp:CASNumber
|
50-12-4
|
|
gptkbp:chemicalFormula
|
C12H12N2O2
|
|
gptkbp:contraindication
|
porphyria
|
|
gptkbp:discoveredBy
|
gptkb:H._Houston_Merritt
gptkb:Tracy_Putnam
|
|
gptkbp:discoveredIn
|
1940s
|
|
gptkbp:eliminationHalfLife
|
7-15 hours
|
|
gptkbp:hasInChIKey
|
QXDMGPKYFZVEMY-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CC1(C(=O)NC(=O)N1C)C2=CC=CC=C2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
mephenytoin
|
|
gptkbp:IUPACName
|
5-ethyl-3-methyl-5-phenyl-imidazolidine-2,4-dione
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:meltingPoint
|
162-164°C
|
|
gptkbp:metabolism
|
gptkb:CYP2C19
|
|
gptkbp:molecularWeight
|
216.24 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
4057
CHEMBL1201
3917
DB00334
|
|
gptkbp:relatedTo
|
gptkb:phenytoin
ethotoin
|
|
gptkbp:retired
|
risk of severe adverse effects
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
rash
drowsiness
ataxia
|
|
gptkbp:status
|
withdrawn in many countries
|
|
gptkbp:synonym
|
3-methyl-5-ethyl-5-phenylhydantoin
Mesantoin
|
|
gptkbp:UNII
|
6Q6P4776YS
|
|
gptkbp:usedFor
|
treatment of epilepsy
|
|
gptkbp:bfsParent
|
gptkb:CYP2C19
|
|
gptkbp:bfsLayer
|
6
|